HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTC BB: ARDM.OB) (the “Company”) today announced financial results for the second quarter and six months ended June 30, 2011. Total revenue was approximately $0.2 million for the second quarter of 2011, compared with no revenue for the second quarter of 2010. Revenue for the second quarter of 2011 reflects the quarterly royalty payment from Zogenix for product sales of SUMAVEL® DosePro™ needle-free delivery system for treatment of acute migraine and cluster headaches.
